Deep Ganglionic Hemorrhage on a Factor Xa Inhibitor With a Distressed Family
A 71-year-old man with atrial fibrillation, prior myocardial infarction, and hypertension is brought in after sudden left-sided weakness and rightward gaze deviation. He took apixaban 5 mg twice daily, with the last dose about 5 hours before symptom onset, and has continued aspirin 81 mg daily since his myocardial infarction. Blood pressure is 208/106 mm Hg, GCS 13 (E3 V4 M6), and he localizes on the right and withdraws on the left. Noncontrast CT shows a 35 mL right basal ganglia hemorrhage with 4 mm of midline shift, no intraventricular blood, and no hydrocephalus. Creatinine clearance is 45 mL/min, platelets 210,000, INR 1.1. His daughter asks whether "the blood thinner can be reversed," and the resident asks about platelet transfusion and surgical evacuation.
1. Define your blood pressure target and the agent and method you would use, with the reasoning behind the target you chose.
Read the worked answer
Target: a smooth reduction to systolic about 140 mm Hg (a range of 130–150), achieved over 1–2 hours and held.
Why not lower? ATACH-2 randomized a target of 110–139 versus 140–179 mm Hg and found no reduction in hematoma expansion or death and disability, with more renal adverse events in the intensive arm. INTERACT2 found no significant difference in the primary outcome, though there was a suggestion of better functional outcome with intensive lowering. Taken together, there is no evidence that driving systolic below 130 helps, and the perihematomal tissue plus a brain with 4 mm of shift may depend on perfusion pressure. In a patient with chronic hypertension, the autoregulatory curve is shifted upward, making an abrupt drop below 130 particularly risky.
Why not higher? Observational data link higher peak systolic pressure to hematoma growth, and sustained pressure above 160–180 mm Hg is consistently associated with worse outcomes.
How: insert an arterial line, then use a nicardipine infusion titrated in small increments. Avoid intravenous labetalol boluses stacked on top of an infusion, which cause overshoot and swings. Avoid sodium nitroprusside, which raises intracranial pressure and carries cyanide risk in renal impairment. Recheck the CT if the patient worsens neurologically; do not chase the number at the expense of the examination.
2. Should the apixaban be reversed, with what agent, and what is your position on platelet transfusion and the continued aspirin?
Read the worked answer
Yes - reversal is indicated. He has an intracranial hemorrhage and took a factor Xa inhibitor within roughly one half-life.
Agent choice:
- Andexanet alfa is the specific reversal agent and would be preferred where available; for apixaban 5 mg, the low-dose regimen (400 mg bolus) applies. It improves hemostatic efficacy, but in the ANNEXA-I trial it increased thrombotic events, and it has not been shown to improve functional outcome - so the decision should be framed as controlling expansion in a patient with a potentially devastating bleed, not as a guaranteed benefit.
- If andexanet is unavailable or contraindicated, give four-factor prothrombin complex concentrate at approximately 50 units/kg. This is the guideline-endorsed alternative, though its effect on expansion is modest.
- Do not give fresh frozen plasma, vitamin K, or platelet transfusion for a factor Xa inhibitor. Platelets have no target in this pharmacology.
Aspirin: stop it. The PATCH trial showed that platelet transfusion in patients on antiplatelet therapy with intracerebral hemorrhage worsened outcomes, and continuing aspirin adds bleeding risk without an acute ischemic benefit.
Counseling point for the daughter: reversal reduces the risk of further bleeding; it does not undo the injury already present, and it carries a small thrombotic risk given his coronary disease and atrial fibrillation.
3. The family asks about surgery, and the resident asks when to discuss prognosis. What do you recommend, and how do you frame the conversation?
Read the worked answer
Surgery: routine open craniotomy and clot evacuation is not indicated. STICH and STICH II showed no benefit for early open evacuation of supratentorial hemorrhage, including lobar clots. Minimally invasive transsulcal evacuation, as tested in ENRICH, improved 180-day functional outcomes for lobar and basal ganglia hemorrhages of roughly 30–80 mL, and this patient's 35 mL basal ganglia clot with a GCS of 13 falls in that range. It is reasonable to offer minimally invasive evacuation at a center that performs it, while making clear that medical management is an acceptable alternative; it is not an emergency tonight, and transferring him for it should not delay stabilization or reversal.
Prognosis discussions: avoid definitive statements within the first 72 hours. Early deterioration is often driven by edema and hematoma expansion, both potentially reversible, and early pessimistic prognostication is a well-documented source of self-fulfilling withdrawal of care. Give the family a structured picture: what has happened, what we are doing, and what the next 24–48 hours will tell us, with an explicit commitment to revisit.
Also in the plan: hold aspirin indefinitely, start mechanical venous thromboembolism prophylaxis now and pharmacologic prophylaxis at roughly 24–48 hours once bleeding is stable, and address blood pressure control and anticoagulation strategy for atrial fibrillation at discharge rather than in the acute phase.